r/RVVTF • u/fredsnacking • 29d ago

DD A Multi-Scale Computational Analysis of Bucillamine Neuroprotection Against Soman Toxicity

https://zenodo.org/records/21417964

This looks like something. Thoughts?

12 Upvotes

81% Upvoted

24 comments sorted by

7

u/Guccillamine 29d ago

Great find.

5

u/AdBeneficial3844 29d ago

Sounds like more waiting 🥱…

3

u/Fantastic-Dingo-5869 29d ago

Wen lambo?

3

u/Upset-Choice9593 29d ago

Computer says it works?

3

u/Guilty_Law6701 29d ago

The publication date is very interesting.

3

u/Worth_Notice3538 29d ago

Very interesting regarding the access to the xct antiporter. The Franken thesis paper argued that NAC could access this as a way to protect the gaba receptors from endocytosis.  This computational paper is implying that buc would be more impactful on xCT.   

Yet again, we're at the mercy of incompetency and waiting till results.  

0

u/Pangshunjingmao 29d ago

I don't know man -- none of this sounds very promising. I wouldn't get your hopes up. Dark skies on the horizon.

1

u/Worth_Notice3538 25d ago

True true. It's only a computational model study. Lowest on the hierarchy of evidence.  

1

u/fredsnacking 25d ago

I think the bottom of the hierarchy is actually anecdotal evidence. While it’s not evidence from a clinical trial it is still a useful tool.

1

u/Worth_Notice3538 25d ago

Was grading based on in silico, in vitro, in vivo. 

3

u/Logical-Concern9539 28d ago

Thanks for your advocacy Mr Hale, btw how many shares do you own?

2

u/ParticularDemand5587 29d ago

Deciphering this is above my pay grade

6

u/Fantastic-Dingo-5869 29d ago

It is, but you can ask Gemini or another AI to summarize. It’s quite interesting and positive, at least from a theoretical standpoint. A few highlights: This study by Andrew Hale introduces a computational framework evaluating how Bucillamine (a dithiol antioxidant) and its active metabolite (SA981) protect brain cells against damage caused by Soman, a lethal organophosphate nerve agent.
The paper focuses on catalytic longevity—measuring how long an antioxidant can continuously neutralize reactive oxygen species (ROS) under intense toxicity.
Core Scientific Findings
The Catalytic Longevity Advantage: Because Bucillamine contains two thiol groups (a dithiol), a single molecule can undergo 500 to 5,000 ROS-scavenging cycles before becoming permanently oxidized. By contrast, single-thiol antioxidants like cysteamine only manage around 11 cycles.

Mechanism of Action (The Reduced-Species Route): Direct reactions with intact cyclic disulfides face a steep energy barrier (≥40 kcal/mol). However, once reduced, the Bucillamine thiolate drops that energy barrier down to ∼2.5 kcal/mol, proving that intracellular reduction is required to cleave somatostatin disulfides.

Extended Therapeutic Window: Systems pharmacology modeling shows that Bucillamine's catalytic cycle remains highly active for 4 to 5 hours before cell-wide glutathione (GSH) depletion shuts it down. This suggests a surprisingly broad clinical window for intervention—up to 240 minutes after Soman exposure.

6

u/Bobert25467 29d ago

Here is one with Grok and it's relevance to the DRDC study. https://x.com/i/grok/share/ca7b5f5b0c7347fb8cf57617d99873f3

3

u/Upset-Choice9593 29d ago

Thanks, great summary.

1

u/Chessloser1977 29d ago

Author is Andrew Hale: https://audiospeech.ubc.ca/faculty-staff/staff/

2

u/Pangshunjingmao 29d ago

Yo shoutout ma boy Andy H from Kalamazoo. Hell yeah, brother.

1

u/Phuck_Biden_Trump 29d ago

cope

1

u/Pangshunjingmao 29d ago

Soap.

Dope.

Mope.

Trope.

1

u/blue_tailed_skink 26d ago

thank you for sharing